Andrés David Aranzazu Ceballos, Lina María Martínez Sánchez, Ana Paulina Pamplona Sierra, Daniela Vergara Yánez, Liliana Franco Hincapié, Richard Baquero Rodriguez
{"title":"儿科患者的原发性血栓性微血管病。","authors":"Andrés David Aranzazu Ceballos, Lina María Martínez Sánchez, Ana Paulina Pamplona Sierra, Daniela Vergara Yánez, Liliana Franco Hincapié, Richard Baquero Rodriguez","doi":"10.1177/2333794X241307535","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background</i>. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. <i>Methodology</i>. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. <i>Results</i>. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. <i>Conclusion</i>. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.</p>","PeriodicalId":12576,"journal":{"name":"Global Pediatric Health","volume":"11 ","pages":"2333794X241307535"},"PeriodicalIF":1.4000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650636/pdf/","citationCount":"0","resultStr":"{\"title\":\"Primary Thrombotic Microangiopathy in Pediatric Patients.\",\"authors\":\"Andrés David Aranzazu Ceballos, Lina María Martínez Sánchez, Ana Paulina Pamplona Sierra, Daniela Vergara Yánez, Liliana Franco Hincapié, Richard Baquero Rodriguez\",\"doi\":\"10.1177/2333794X241307535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Background</i>. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. <i>Methodology</i>. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. <i>Results</i>. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. <i>Conclusion</i>. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.</p>\",\"PeriodicalId\":12576,\"journal\":{\"name\":\"Global Pediatric Health\",\"volume\":\"11 \",\"pages\":\"2333794X241307535\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650636/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Pediatric Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2333794X241307535\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Pediatric Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2333794X241307535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
Primary Thrombotic Microangiopathy in Pediatric Patients.
Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.